Literature DB >> 724343

Chronic salicylate administration in juvenile rheumatoid arthritis: aspirin "hepatitis" and its clinical significance.

J G Schaller.   

Abstract

Salicylates provide the backbone of therapy in juvenile rheumatoid arthritis. They are effective in controlling the disease approximately 75% of the time if they are properly used. Salicylate administration is relatively safe if carefully done. Serum salicylate levels should not exceed 30 mg/dl routinely. Patients, physicians, and parents should be alert to early clinical signs of toxicity. Chief hazards of chronic salicylate administration other than salicylism (which should be uniformly preventable) include gastric irritation with questionable relationship to peptic ulcer disease, and rare serious hepatotoxicity, bleeding diatheses, or hypersensitivity reactions.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 724343

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  6 in total

1.  Aspirin-related hepatotoxicity in a child after liver transplant.

Authors:  T C Chen; K F Ng; L B Jeng; T S Yeh; C M Chen
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

Review 2.  Clinical associations between arthritis and liver disease.

Authors:  P R Mills; R D Sturrock
Journal:  Ann Rheum Dis       Date:  1982-06       Impact factor: 19.103

Review 3.  Differences in NSAID tolerability profiles. Fact or fiction?

Authors:  K J Skeith; M Wright; P Davis
Journal:  Drug Saf       Date:  1994-03       Impact factor: 5.606

Review 4.  Hepatotoxicity of mild analgesics.

Authors:  L F Prescott
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

5.  Sulphasalazine induced hepatitis in juvenile rheumatoid arthritis.

Authors:  D Caspi; D Fuchs; M Yaron
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103

6.  Therapeutic aspirin overdose in a three-year-old boy.

Authors:  D C Brown; J M Savage
Journal:  Ulster Med J       Date:  1987-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.